Now happening in room E451 - upper GI / biliary and #PancreaticCancer rapid oral section hosted by my fantastic colleague and dear friend Grainne O'Kane 🇮🇪 #ASCO24 OncoAlert 🚨 (picture #ASCO23 needs updating)

Now…can #artificalintelligence help to predict response to adjuvant chemotherapy in #PancreticCancer ? New data (retrospective) from the PRODIGE group suggest it could… #pancsm 💜 OncoAlert 🚨 #ASCO24 Anirban Maitra Grainne O'Kane Arndt Vogel

GIANT trial in >70yrs/vulnerable PDAC #ASCO24 as by geriatric assess ➡️imp to remember most on PDAC trials <70yrs ➡️dose modified GnP vs 5FU liposomal irinotecan ➡️ sobering med OS by ITT 4.7 vs 4.4mths ➡️need to identify who can benefit & discuss with pts

PASS-01 trial #PDAC #ASCO24 ➡️rand ph2 mFFX vs.GnP ➡️WGS/RNA/PDO/CTCs/ctDNA ✅PP PFS 5.5 (GnP) vs. 4.0mths (mFFX) ➡️PP ❌gBRCA/PALB2 >KRASWT in GnP ➡️MTB directed 2nd line ➡️ GnP remains a backbone for drug dvp ➡️basal-like unmet need Proud Dr. Amber Habowski as translational leads

NIVO + IPI vs LEN (90%) or SORA as 1st line treatment for HCC #ASCO24 🔎CHECKMATE 9DW, 668 pts 👉ORR 36 vs 13%, DoR 30 vs 13mo 👉mPFS 9.1 vs 9.1 mo 👉mOS 23.7 vs 20.6mo 🧐More options in 1st line HCC, very good data for Lenva & Nivo/Ipi ESMO - Eur. Oncology ILCA EASLnews #livertwitter

“Learn from each trial, understand our patients&their cancer: biology is the king, selection the queen when developing treatments for #PancreaticCancer”. Beautiful summary by Prof David K. Chang of 3 fantastic studies. Huge congratulations to all trial teams👏Grainne O'Kane Efrat Dotan MD NRG Oncology

15 Posts From ASCO 2024 Day 5 You Should Not Miss! Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation Dr. Patrick Hwu Mark Lewis, MD, FASCO Ivy Riano, M.D. Robin Zon, MD, FACP, FASCO Zainab Shinkafi-Bagudu Mohammad Jad Moussa, MD, MSc Paolo Tarantino Rachna Shroff, MD, MS, FASCO Fumiko Ladd Chino, MD, FASCO Nader Sanai Doug Flora MD, LSSBB Grainne O'Kane oncodaily.com/societies/7809… #ASCO24 #ASCO #Cancer #OncoDaily #Oncology

It was a great honour to discuss these 3 trials asking the important questions we face everyday in #PancreaticCancer, and sincere thanks to ASCO organising committee for asking a surgeon to discuss. Huge congratulations to the trial teams for tackling these difficult trials.

At #UKOF2024 today comprehensive summary of therapeutic options for the heterogenous group that comprises biliary tract cancers from Grainne O'Kane. Precision medicine promises being realised in a fast moving field.

Really important to have SBRT available to patients with #HCC and now another bridging option pre LT 👇🏻 ➡️how will LRT integrate with ICI Aisling Barry Laura Dawson HPB Dublin Gonzalo Sapisochin

Congrats Ronan Andrew McLaughlin on the 🇨🇦 Young Investigator Award, aimed at investigating GATA6 expression as a biomarker in pancreatic cancer! Great work🏆 University Health Network Princess Margaret Cancer Centre Grainne O'Kane #ASCO24 Royal College of Physicians of Ireland RCPI_Trainees #IrishOncologists🇮🇪

Thomas Seufferlein review the role of personalised medicine in the PDAC educational session in #ESMOGI24 ➡️NGS testing make sense, but is not the only means ➡️targeting KRAS may be a game changer ➡️importance of molecular tumor board #ESMOAmbassadors, ESMO - Eur. Oncology

'Survival for patients with #PancreaticCancer is slowly improving. Collaboration of scientists, researchers & clinicians has led to better understanding of the complex disease biology - collaborations that must ensue on local & global levels to realise progress' Prof. Grainne O'Kane

BIG KRAS day today at Cancer Discovery!! First study led by Andrew Aguirre Dilly Julien and colleagues at Hale Family Center For Pancreatic Cancer Research MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Koch Institute at MIT Mechanisms of resistance to oncogenic KRAS inhibition in #PancreaticCancer aacrjournals.org/cancerdiscover… In this study

Such an exciting time! Likely game-changer in #PDAC 👇🏻#KRASi ➡️hopefully we can understand who will respond, who will need combinations ➡️how will subtypes and RAS dosage influence response? ➡️how can we help more patients access trials! Pancreatic Cancer Ireland Pancreatic Cancer Europe (PCE) Notta Lab

📣Celiac plexus (CP) pain is a debilitating cancer related pain. Tx options are limited. The Lancet Oncology #CP radiosurgery - ➡️90pts with >5/11BPI ➡️92% pancreatic ca ➡️25Gy single dose ➡️Significant pain imp ３週間チャレンジ ➡️11 poss/prob G3+ s-e sciencedirect.com/science/articl… Yaacov Lawrence Md